We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Hands Warning Letters to Three Surgical Mesh Makers

FDA Hands Warning Letters to Three Surgical Mesh Makers

June 12, 2015

Three medical devicemakers received FDA warning letters for marketing surgical mesh for off-label use in breast surgery.

In a June 1 letter to Allergan, the agency cites the company for promoting its SERI Surgical Scaffold for use in breast revision surgeries, breast lift procedures with or without augmentation, and breast reductions. The FDA cleared the scaffold for use as general soft tissue reinforcement, the letter notes.

A same day letter to Bridgewater, N.J.-based LifeCell letter accuses the company of promoting its Strattice Tissue Matrix for use in breast reconstructive surgery and breast augmentation, although it was cleared only for use as a soft tissue patch to reinforce weak soft tissue or repair damaged or ruptured soft tissue membranes. This is a major alteration to its intended use, the FDA says.

Similarly, TEI Biosciences’ SurgiMend was cleared for plastic and reconstructive surgery, muscle flap reinforcement or hernia repair, but the firm marketed it as the superior biologic matrix for breast surgery patients, the May 29 warning letter says.

The agency wants all three companies to stop distributing the devices for use in breast surgery and submit remediation plans within 15 business days.

The companies couldn’t be reached for comment by press time. View the warning letters at www.fdanews.com/06-06-15-allergan.pdf; www.fdanews.com/06-15-15-lifecell.pdf; and www.fdanews.com/06-06-15-TEI.pdf. — Elizabeth Orr

Postmarket Safety

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing